{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:59:56Z","timestamp":1793642396121,"version":"4.5.1"},"reference-count":88,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Depression is a common mental disorder in children and adolescents, and antidepressants are widely used for treatment. This study aimed to explore and analyze adverse events (AEs) associated with antidepressant use in this population, providing insights for safety assessment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study extracted AE reports from the US FDA Adverse Event Reporting System (FAERS) for children and adolescents aged 6\u201317 years from 2014\u20132023, with fluoxetine, escitalopram, and sertraline as the primary suspected drugs. The study used the International Dictionary of Medical Terminology (MedDRA) to encode and classify AEs, and employed the reporting odds ratio (ROR) and proportional reporting ratio (PRR) methods for data mining.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The FAERS database included 9,845 AE reports involving fluoxetine, escitalopram, and sertraline among children and adolescents aged 6\u201317 years. After removing duplicates, the analysis yielded 1,604, 352, and 571 AEs for fluoxetine, escitalopram, and sertraline, respectively. The study population demonstrated a sex distribution with approximately twice as many female patients as male patients, with most patients aged 12\u201317 years. At the system organ class (SOC) level, the AEs predominantly involved psychiatric disorders and nervous system disorders. Within the psychiatric disorders category at the high level group term (HLGT) level, the most frequently reported AE signals across all three medications were suicidal and self-injurious behaviors (not elsewhere classified, hereinafter referred to as NEC) and anxiety disorders and symptoms; For nervous system disorders, the predominant AE signals were neurological disorders (NEC) and movement disorders (including parkinsonism). At the Preferred Term (PT) level, the three antidepressants demonstrated similar AEs, including various suicidal and self-injurious behaviors, intentional overdose, neurological disorders (including serotonin syndrome, extravertebral reactions, etc) and prolonged QT. The typical AEs of fluoxetine included decreased appetite, insomnia, and urinary retention. Escitalopram was associated with additional AEs of sexual dysfunction and toxic epidermal necrolysis, whereas sertraline demonstrated unique associations with headache and rhabdomyolysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>This study may offer further evidence regarding AEs associated with commonly prescribed antidepressants in children and adolescents. Overall, the findings are mostly consistent with the AEs recorded in the packaging instructions and previous reports. However, the study also identified previously unreported AEs and highlighted variations in the AE profiles across different demographic groups. As the causal relationships between these medications and the observed AEs remain to be fully elucidated, additional research is warranted to confirm these findings.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0330025","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T18:21:47Z","timestamp":1755109307000},"page":"e0330025","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety of antidepressants commonly used in 6\u201317-year-old children and adolescents: A disproportionality analysis from 2014\u20132023 on the basis of the FAERS database"],"prefix":"10.1371","volume":"20","author":[{"given":"Yan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinchuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4560-8810","authenticated-orcid":true,"given":"Ya","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"6","key":"pone.0330025.ref001","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1037\/amp0000904","article-title":"Summary of the clinical practice guideline for the treatment of depression across three age cohorts","volume":"77","author":"Guideline Development Panel for the Treatment of Depressive Disorders","year":"2022","journal-title":"Am Psychol"},{"issue":"9995","key":"pone.0330025.ref002","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Global Burden of Disease Study 2013 Collaborators","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"pone.0330025.ref003","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1469-7610.2006.01682.x","article-title":"Is there an epidemic of child or adolescent depression?","volume":"47","author":"E Jane Costello","year":"2006","journal-title":"J Child Psychol Psychiatry"},{"issue":"6","key":"pone.0330025.ref004","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-1878","article-title":"National trends in the prevalence and treatment of depression in adolescents and young adults","volume":"138","author":"R Mojtabai","year":"2016","journal-title":"Pediatrics"},{"issue":"12","key":"pone.0330025.ref005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archpsyc.60.12.1236","article-title":"Outpatient treatment of child and adolescent depression in the United States","volume":"60","author":"M Olfson","year":"2003","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"pone.0330025.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjb.2017.2","article-title":"Antidepressants in paediatric depression: do not look back in anger but around in awareness","volume":"42","author":"DA Brent","year":"2018","journal-title":"BJPsych Bull"},{"issue":"5","key":"pone.0330025.ref007","article-title":"New generation antidepressants for depression in children and adolescents: a network meta-analysis","volume":"5","author":"SE Hetrick","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"pone.0330025.ref008","article-title":"Newer generation antidepressants for depressive disorders in children and adolescents","volume":"11","author":"SE Hetrick","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0330025.ref009","article-title":"Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence","volume":"351","author":"J Le Noury","year":"2015","journal-title":"BMJ"},{"issue":"10047","key":"pone.0330025.ref010","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","article-title":"Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis","volume":"388","author":"A Cipriani","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"pone.0330025.ref011","article-title":"Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management","volume":"120","author":"GLAD-PC Steering Group","year":"2007","journal-title":"Pediatrics"},{"key":"pone.0330025.ref012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/psychiatry.IndianJPsychiatry_563_18","article-title":"Clinical practice guidelines for the management of depression in children and adolescents","volume":"61","author":"S Grover","year":"2019","journal-title":"Indian J Psychiatry"},{"issue":"3","key":"pone.0330025.ref013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"AN Edinoff","year":"2021","journal-title":"Neurol Int"},{"key":"pone.0330025.ref014","unstructured":"FDA. Suicidality in children and adolescents being treated with antidepressant medications. 2007. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/suicidality-children-and-adolescents-being-treated-antidepressant-medications"},{"issue":"23","key":"pone.0330025.ref015","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMp078015","article-title":"Expanding the black box - depression, antidepressants, and the risk of suicide","volume":"356","author":"RA Friedman","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0330025.ref016","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/pds.3420","article-title":"Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events","volume":"22","author":"AS Czaja","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0330025.ref017","doi-asserted-by":"crossref","first-page":"115300","DOI":"10.1016\/j.psychres.2023.115300","article-title":"Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS","volume":"326","author":"Y Chen","year":"2023","journal-title":"Psychiatry Res"},{"key":"pone.0330025.ref018","doi-asserted-by":"crossref","first-page":"1178646919873925","DOI":"10.1177\/1178646919873925","article-title":"Serotonin syndrome: pathophysiology, clinical features, management, and potential future directions","volume":"12","author":"WJ Scotton","year":"2019","journal-title":"Int J Tryptophan Res"},{"issue":"2","key":"pone.0330025.ref019","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1060028018794005","article-title":"Clinical management of bleeding risk with antidepressants","volume":"53","author":"AL Bixby","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"3","key":"pone.0330025.ref020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.psc.2016.04.010","article-title":"Serotonin reuptake inhibitors and risk of abnormal bleeding","volume":"39","author":"C Andrade","year":"2016","journal-title":"Psychiatr Clin North Am"},{"key":"pone.0330025.ref021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2016.08.017","article-title":"Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies","volume":"118","author":"S Laporte","year":"2017","journal-title":"Pharmacol Res"},{"issue":"5","key":"pone.0330025.ref022","article-title":"Antidepressants and the risk of hyponatremia: a Danish register-based population study","volume":"6","author":"KB Leth-M\u00f8ller","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0330025.ref023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjmed.2017.07.025","article-title":"Differences in associations of antidepressants and hospitalization due to hyponatremia","volume":"131","author":"S Farmand","year":"2018","journal-title":"Am J Med"},{"key":"pone.0330025.ref024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jad.2017.03.044","article-title":"Antidepressants and risk of cataract development: A population-based, nested case-control study","volume":"215","author":"P-H Chou","year":"2017","journal-title":"J Affect Disord"},{"issue":"1","key":"pone.0330025.ref025","doi-asserted-by":"crossref","first-page":"12257","DOI":"10.1038\/s41598-023-39482-y","article-title":"Exploring the association between selective serotonin reuptake inhibitors and rhabdomyolysis risk based on the FDA pharmacovigilance database","volume":"13","author":"Y Wang","year":"2023","journal-title":"Sci Rep"},{"issue":"5","key":"pone.0330025.ref026","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s43441-023-00542-0","article-title":"Characterization of pediatric reports in the US food and drug administration adverse event reporting system from 2010-2020: a cross-sectional study","volume":"57","author":"M Phan","year":"2023","journal-title":"Ther Innov Regul Sci"},{"issue":"12","key":"pone.0330025.ref027","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00228-020-02970-5","article-title":"Safety of fluoxetine use in children and adolescents: a disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database","volume":"76","author":"IN Christodoulos","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"pone.0330025.ref028","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1177\/10600280241231116","article-title":"Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on FDA adverse event reporting system","volume":"58","author":"Y Zhao","year":"2024","journal-title":"Ann Pharmacother"},{"key":"pone.0330025.ref029","unstructured":"FDA. Selective Serotonin Reuptake Inhibitors (SSRIs) Information. 2014. https:\/\/www.fda.gov\/drugs\/information-drug-class\/selective-serotonin-reuptake-inhibitors-ssris-information"},{"key":"pone.0330025.ref030","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, De F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). 2012.","DOI":"10.5772\/50095"},{"key":"pone.0330025.ref031","doi-asserted-by":"crossref","first-page":"24955","DOI":"10.1038\/srep24955","article-title":"Systematic analysis of adverse event reports for sex differences in adverse drug events","volume":"6","author":"Y Yu","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0330025.ref032","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40360-023-00664-z","article-title":"Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases","volume":"24","author":"D Dubrall","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"pone.0330025.ref033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0278-5846(03)00177-5","article-title":"Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders","volume":"28","author":"E Baca","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"pone.0330025.ref034","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40262-014-0145-2","article-title":"Sex differences in the pharmacokinetics of antidepressants: influence of female sex hormones and oral contraceptives","volume":"53","author":"VA Damoiseaux","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0330025.ref035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/apt.13329","article-title":"Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol","volume":"42","author":"YT Wang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"pone.0330025.ref036","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"I Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"issue":"9","key":"pone.0330025.ref037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0006-3223(98)00162-0","article-title":"Estrogen-serotonin interactions: implications for affective regulation","volume":"44","author":"DR Rubinow","year":"1998","journal-title":"Biol Psychiatry"},{"issue":"11","key":"pone.0330025.ref038","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41583-021-00513-0","article-title":"Sex differences in anxiety and depression: circuits and mechanisms","volume":"22","author":"DA Bangasser","year":"2021","journal-title":"Nat Rev Neurosci"},{"key":"pone.0330025.ref039","doi-asserted-by":"crossref","first-page":"1052702","DOI":"10.3389\/fpsyg.2022.1052702","article-title":"Causes of the male-female ratio of depression based on the psychosocial factors","volume":"13","author":"J Tang","year":"2022","journal-title":"Front Psychol"},{"issue":"2","key":"pone.0330025.ref040","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.physbeh.2009.02.033","article-title":"Sex differences in psychopathology: of gonads, adrenals and mental illness","volume":"97","author":"MB Solomon","year":"2009","journal-title":"Physiol Behav"},{"issue":"10352","key":"pone.0330025.ref041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(22)01012-1","article-title":"Depression in young people","volume":"400","author":"A Thapar","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"pone.0330025.ref042","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.acap.2024.10.008","article-title":"Selective serotonin reuptake inhibitor prescribing within an integrated pediatric primary care behavioral health program","volume":"25","author":"L Vernacchio","year":"2025","journal-title":"Acad Pediatr"},{"issue":"7","key":"pone.0330025.ref043","article-title":"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study","volume":"17","author":"RH Jack","year":"2020","journal-title":"PLoS Med"},{"issue":"5","key":"pone.0330025.ref044","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1192\/bjp.bp.115.166975","article-title":"Initiation and duration of selective serotonin reuptake inhibitor prescribing over time: UK cohort study","volume":"209","author":"RL McCrea","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"15","key":"pone.0330025.ref045","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1517\/14656566.2012.726613","article-title":"An update on antidepressant use and suicidality in pediatric depression","volume":"13","author":"C Adegbite-Adeniyi","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"pone.0330025.ref046","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.psc.2016.04.002","article-title":"Antidepressants and Suicidality","volume":"39","author":"DA Brent","year":"2016","journal-title":"Psychiatr Clin North Am"},{"issue":"2","key":"pone.0330025.ref047","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00228-023-03596-z","article-title":"Serotonin syndrome: a pharmacovigilance comparative study of drugs affecting serotonin levels","volume":"80","author":"C Elli","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0330025.ref048","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bcpt.13912","article-title":"Serotonin syndrome-A focused review","volume":"133","author":"N Mikkelsen","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"pone.0330025.ref049","doi-asserted-by":"crossref","first-page":"810","DOI":"10.3949\/ccjm.83a.15129","article-title":"Serotonin syndrome: preventing, recognizing, and treating it","volume":"83","author":"RZ Wang","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"pone.0330025.ref050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ajem.2022.08.030","article-title":"High risk and low prevalence diseases: serotonin syndrome","volume":"61","author":"A Spadaro","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"4","key":"pone.0330025.ref051","first-page":"554","article-title":"Serotonin syndrome with fluoxetine: two case reports","volume":"16","author":"DD Patel","year":"2016","journal-title":"Ochsner J"},{"issue":"6","key":"pone.0330025.ref052","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1192\/bjp.165.6.728","article-title":"Extrapyramidal symptoms with selective serotonin reuptake inhibitors","volume":"165","author":"DK Arya","year":"1994","journal-title":"Br J Psychiatry"},{"issue":"5","key":"pone.0330025.ref053","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaad.2006.10.020","article-title":"Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors","volume":"56","author":"D Krasowska","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"pone.0330025.ref054","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1176\/ajp.152.1.122","article-title":"Fluoxetine and extrapyramidal side effects","volume":"152","author":"DM Coulter","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"22","key":"pone.0330025.ref055","article-title":"Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: a network meta-analysis of randomized controlled trials","volume":"98","author":"S Guo","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"pone.0330025.ref056","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1176\/appi.ajp.163.2.325","article-title":"QTc prolongation and torsades de pointes in an elderly woman taking fluoxetine","volume":"163","author":"I Wilting","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"2","key":"pone.0330025.ref057","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2125.2012.04415.x","article-title":"Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter?","volume":"75","author":"RR Shah","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"pone.0330025.ref058","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with Selective Serotonin Reuptake Inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"S Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"pone.0330025.ref059","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.psychres.2017.06.038","article-title":"Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database","volume":"256","author":"S Kim","year":"2017","journal-title":"Psychiatry Res"},{"issue":"3","key":"pone.0330025.ref060","article-title":"Efficacy and safety of fluoxetine in autism spectrum disorder: a meta-analysis","volume":"27","author":"C Li","year":"2020","journal-title":"Am J Ther"},{"issue":"3","key":"pone.0330025.ref061","article-title":"Fluoxetine-induced acute urinary retention in a child with depression","volume":"25","author":"NJ Haridas","year":"2023","journal-title":"Prim Care Companion CNS Disord"},{"issue":"3","key":"pone.0330025.ref062","first-page":"246","article-title":"Fluoxetine related urinary retention in a 15-year-old girl: a case report","volume":"59","author":"\u00d6F Bulut","year":"2022","journal-title":"Noro Psikiyatr Ars"},{"issue":"8","key":"pone.0330025.ref063","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1089\/cap.2015.0134","article-title":"Urinary retention in an adolescent patient caused by fluoxetine alone","volume":"25","author":"M Karadag","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"pone.0330025.ref064","first-page":"643","article-title":"Urinary retention in adults: diagnosis and initial management","volume":"77","author":"BA Selius","year":"2008","journal-title":"Am Fam Physician"},{"issue":"6","key":"pone.0330025.ref065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/02698811241249651","article-title":"Unveiling potential adverse events associated with escitalopram oxalate: a real-world analysis based FDA adverse event reporting system database","volume":"38","author":"Y Jiang","year":"2024","journal-title":"J Psychopharmacol"},{"issue":"4","key":"pone.0330025.ref066","doi-asserted-by":"crossref","first-page":"191","DOI":"10.9740\/mhc.2016.07.191","article-title":"Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review","volume":"6","author":"E Jing","year":"2016","journal-title":"Ment Health Clin"},{"issue":"4","key":"pone.0330025.ref067","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","article-title":"Prevalence of sexual dysfunction among newer antidepressants","volume":"63","author":"AH Clayton","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"pone.0330025.ref068","article-title":"Effect of antidepressants on ejaculation dysfunction in patients with depression and anxiety: a systematic review and network meta-analysis","author":"Q Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0330025.ref069","doi-asserted-by":"crossref","first-page":"1259611","DOI":"10.3389\/fphar.2023.1259611","article-title":"Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database","volume":"14","author":"D Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"pone.0330025.ref070","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/1060028013501994","article-title":"A comparison of the risk of QT prolongation among SSRIs","volume":"47","author":"KA Funk","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"11","key":"pone.0330025.ref071","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","article-title":"The cardiovascular safety profile of escitalopram","volume":"23","author":"ME Thase","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"pone.0330025.ref072","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jid.2016.03.023","article-title":"Morbidity and mortality of stevens-johnson syndrome and toxic epidermal necrolysis in United States Adults","volume":"136","author":"DY Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"5","key":"pone.0330025.ref073","first-page":"441","article-title":"Lyell syndrome or toxic epidermal necrolysis and Stevens-Johnson syndrome after treatment with fluoxetine","volume":"47","author":"I Bodokh","year":"1992","journal-title":"Therapie"},{"issue":"1","key":"pone.0330025.ref074","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/jcp.0b013e3181604015","article-title":"Toxic epidermal necrolysis and fluoxetine: a case report","volume":"28","author":"GW Jonsson","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"pone.0330025.ref075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/000155599750010472","article-title":"Stevens-Johnson syndrome after sertraline","volume":"79","author":"V Jan","year":"1999","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"pone.0330025.ref076","doi-asserted-by":"crossref","first-page":"2369319","DOI":"10.1080\/20523211.2024.2369319","article-title":"Use and misuse of psychoactive medicines: a descriptive cross-sectional study in a densely populated region of Portugal","volume":"17","author":"A Carmona Ara\u00fajo","year":"2024","journal-title":"J Pharm Policy Pract"},{"issue":"15","key":"pone.0330025.ref077","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials","volume":"297","author":"JA Bridge","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"pone.0330025.ref078","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults","volume":"2015","author":"R Banzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0330025.ref079","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002919.pub2","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches","author":"PL Moja","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0330025.ref080","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults","volume":"4","author":"R Banzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0330025.ref081","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1081\/CLT-120037428","article-title":"Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose","volume":"42","author":"GK Isbister","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"pone.0330025.ref082","first-page":"897902","article-title":"Serotonin syndrome after sertraline overdose in a child: a case report","volume":"2013","author":"J Grenha","year":"2013","journal-title":"Case Rep Pediatr"},{"issue":"2","key":"pone.0330025.ref083","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000196","article-title":"Sertraline-Induced Rhabdomyolysis: A Case Report and Literature Review","volume":"23","author":"M Snyder","year":"2016","journal-title":"Am J Ther"},{"issue":"5","key":"pone.0330025.ref084","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajem.2005.05.001","article-title":"2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System","volume":"23","author":"WA Watson","year":"2005","journal-title":"Am J Emerg Med"},{"issue":"6","key":"pone.0330025.ref085","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000001540","article-title":"Sertraline-associated rhabdomyolysis","volume":"30","author":"C Cottone","year":"2023","journal-title":"Am J Ther"},{"issue":"4","key":"pone.0330025.ref086","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-0804","article-title":"Sertraline-induced rhabdomyolysis, trismus, and cardiac arrest in a child","volume":"142","author":"PJ Holmberg","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"pone.0330025.ref087","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0028-3886.222860","article-title":"Sertraline-induced reversible myopathy with rhabdomyolysis and trismus","volume":"66","author":"BV Maramattom","year":"2018","journal-title":"Neurol India"},{"issue":"5","key":"pone.0330025.ref088","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0196-0644(00)66384-9","article-title":"Massive sertraline overdose","volume":"36","author":"DH Brendel","year":"2000","journal-title":"Ann Emerg Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T18:22:00Z","timestamp":1755109320000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330025"}},"subtitle":[],"editor":[{"given":"Hira","family":"Rafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":88,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330025","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}